Colchicine for Diabetic Nephropathy Trial

NCT ID: NCT02442921

Last Updated: 2017-05-09

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-02-22
• Study Completion Date: 2019-04-30

Brief Summary

Forty patients with diabetic nephropathy will be treated with colchicine up to 2 mg, or placebo, for 18 months. A follow up will be performed after 12 additional months. The primary outcome will be a significant reduction or stabilization of proteinuria during the 18 month treatment period.

Detailed Description

Diabetic nephropathy is the leading cause today for end stage renal failure in the western world. Multifactorial intervention in patients may slow the rate of albuminuria and renal injury; however several new drug trials have failed so far to significantly attenuate its progression. Several pathways are identified in the development of diabetic nephropathy, however, in recent years many researchers suspect that inflammatory pathways play central roles in the progression of diabetic neuropathy . There is compelling evidence that diabetes mellitus has an auto-inflammatory component with Nlrp3 inflammasome and interleukin -1 β activation. Colchicine is a relatively safe anti-inflammatory drug used to treat and reverse albuminuria in familial Mediterranean fever nephropathy, an auto-inflammatory disease. Data from one study demonstrated that colchicine diminished proteinuria and inflammation in experimental-diabetic animal models.

Working hypothesis and aims:

To assess whether colchicine reduces proteinuria in diabetic patients with diabetic neuropathy , despite maximal multi-factorial interventions (angiotensin-converting-enzyme inhibitors, tight glycemic and hypertensive control, lifestyle intervention, etc.).

Methods:

Forty patients with stable diabetes, and diabetic neuropathy with proteinuria of 0.5-6g/24 hours, despite standard treatment, will receive colchicine (n=20) or placebo (n=20) for 18 months. Urinary protein and creatinine clearance will be assessed three months before the study initiation, at baseline and every three months thereafter. Blood creatinine, complete blood count, creatine phosphokinase , liver function tests, fasting Glucose Test, HbA1c, and urine protein/creatinine ratio and diabetes mellitus treatment monitoring and follow-up will be performed every three months. Oral colchicine treatment will be initiated at 1mg per day, and increased gradually to 2 mg, if gastrointestinal or musculoskeletal disturbances are absent or tolerated. The participants will be called and evaluated a year after the end of treatment for all parameters mentioned. Statistical analysis will be performed by a statistician.

Expected results:

A significant reduction or stabilization of proteinuria during the 18 month treatment period, or at follow up at one year later.

Importance and Relevance to the call This study may define a new treatment for diabetic nephropathy.

Conditions

Diabetic Nephropathies

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Colchicine

20 patients will receive up to 2 mg of colchicine for 18 months

Group Type: EXPERIMENTAL

Colchicine

Intervention Type: DRUG

up to 2mg of Colchicine daily

Placebo

20 patients will receive placebo for 18 months

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Daily placebo

Interventions

Colchicine

up to 2mg of Colchicine daily

Intervention Type: DRUG

Placebo

Daily placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Patients with diabetes mellitus , age>18 years old, able to sign an informed consent.

2. Hemoglobin A1c in the range of 6-9%, stable for last year (0.5±)

3. Blood creatinine lower than 2 mg/dL.

4. Blood pressure lower than 140/90 mmHg on stable anti-hypertensive treatment for at least 3 months.

5. Treated with ACE or angiotensin II receptor blocker , unless contraindicated

Exclusion Criteria

1. Malignancy or significant heart, lung or liver disease.

2. Any GI disease, inflammatory bowel disease , malnutrition ( BMI under 18 )

3. Psychiatric disease

4. Any muscle disease, history of rhabdomyolysis , myopathy or myositis.

5. Any disease causing renal injury/proteinuria apart from diabetes mellitus

6. Any inflammatory or autoimmune disease

7. Any infection during the last month.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

D-Cure, Israel

INDUSTRY

Sponsor Role: collaborator

Sheba Medical Center

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Shaye Kivity, MD

Role: PRINCIPAL_INVESTIGATOR

Sheba Medical Center

Locations

Sheba Medical Center

Ramat Gan, , Israel

Site Status: RECRUITING

Countries

Israel

Central Contacts

Shaye Kivity, MD

Role: CONTACT

kivitys@gmail.com

0526668143

Naomi Friedman, Ms.c

Role: CONTACT

naomi.friedman@sheba.health.gov.il

Facility Contacts

Shaye Kivity, MD

Role: primary

kivitys@gmail.com

0526668134

Naomi Friedman, M.sc

Role: backup

naomi.friedman@sheba.health.gov.il

+972544451556

Other Identifiers

SHEBA-2015-1560-SK-CTIL

Identifier Type: -

Identifier Source: org_study_id